Case 2: Antiretroviral Regimens for Initial Therapy - Antiretroviral Rx

Case-Based Modules
Initial Evaluation
Dermatologic Manifestations
Oral Manifestations
OIs: Prophylaxis
OIs: Treatment
Antiretroviral Rx
Antiretroviral Rx: Resistance
Antiretroviral Rx: Adverse Effects
Drug-Drug Interactions
Postexposure Prophylaxis
Perinatal Transmission
Special Populations
Prevention for Positives
Challenging Unknowns
Interactive Tutorials
This program is funded through Health Resources and Services Administration, US Department of Health and Human Services.

Home
About This Site
Free CME
AETC NRC
Resources
Feedback
Site Map
Authors

Question | Discussion | References | CME Credit

Case 2: Antiretroviral Regimens

You answered:

	Zidovudine-lamivudine (Combivir) plus efavirenz (Sustiva) is considered a preferred regimen.

This answer is incorrect. Although the regimen zidovudine-lamivudine plus efavirenz was previously a preferred and widely used regimen, it is no longer considered a preferred regimen because the zidovudine-lamivudine component has been demoted to alternative status. The NNRTI efavirenz is considered the preferred NNRTI.

Choose another answer:

	Tenofovir-emtricitabine (Truvada) plus ritonavir (Norvir) plus darunavir (Prezista) is considered a preferred regimen.
	Abacavir (Ziagen) plus tenofovir (Viread) plus lamivudine (Epivir) is considered an alternative regimen.
	Stavudine (Zerit) plus lamivudine (Epivir) plus lopinavir-ritonavir (Kaletra) is considered a preferred regimen.

[Back to Case 2 Question | Go to Correct Answer]